MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Eric J. Dippel, MD, FACC
The esteemed interventional cardiologist and EXCITE ISR study PI shares his insights on restenosis treatments, peripheral embolic protection, and physician-industry partnerships.
Sponsored by Spectranetics Corporation
Defining a Paradigm for Femoropopliteal In-Stent Restenosis
By Craig Walker, MD, and Eric J. Dippel, MD, FACC
Atherectomy for Femoropopliteal In-Stent Restenosis
A review of the current data on the role of atherectomy devices in debulking these difficult lesions.
By Eric J. Dippel, MD, FACC, and Nicolas W. Shammas, MD, MS, FACC
Initial Results Published for Spectranetics' EXCITE ISR Trial
December 10, 2014—Initial results from the EXCITE ISR (Excimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis) trial were published by Eric J. Dippel, MD, et al online ahead of print in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
Spectranetics Presents EXCITE ISR Data on Laser Atherectomy
June 4, 2014—Spectranetics, Inc. announced that findings from the EXCITE ISR (Excimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis) study demonstrated significant procedural advantage of the company’s laser atherectomy system plus percutaneous transluminal angioplasty (PTA).
Spectranetics to Initiate EXCITE ISR Trial
April 7, 2011—Spectranetics Corporation (Colorado Springs, CO) announced that it plans to initiate the EXCITE ISR (Excimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis) clinical trial following the recent conditional approval of the company's investigational device exemption application by the US Food and Drug Administration.
Spectranetics to Initiate EXCITE ISR Clinical Trial
April 7, 2011—Spectranetics Corporation (Colorado Springs, CO) announced that it plans to initiate the EXCITE ISR (Excimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis) clinical trial following the recent conditional approval of the company's investigational device exemption application by the US Food and Drug Administration.
Spectranetics Applies for FDA Clearance With Early Success of EXCITE ISR Trial
March 27, 2014—Spectranetics Corporation (Colorado Springs, CO) announced that with the conclusion of enrollment and early success of the EXCITE ISR clinical trial, it is submitting an application to the US Food and Drug Administration (FDA) for 510(k) clearance of the company’s laser atherectomy system used with percutaneous transluminal angioplasty (PTA) in the treatment of in-stent restenosis.
Spectranetics Achieves Statistical Endpoints of EXCITE ISR Adjunct Analysis
February 24, 2014—Spectranetics Corporation (Colorado Springs, CO) announced that the EXCITE ISR trial achieved the statistical endpoints of the adjunct analysis.
The Restenosis Conundrum
By John R. Laird, MD
Updates in SFA Atherectomy and Thrombectomy
New tools are emerging, but what about data?
By Sreekumar Madassery, MD, and Eric C. King, MD
Surgical Versus Endovascular Revascularization in the Critical Limb Ischemia Patient
Guiding treatment decisions based on lesion characteristics, patient characteristics, and indications for intervention.
By Eric C. Scott, MD
Treating In-Stent Restenosis: Case Report and Future Perspectives
Prevention of in-stent restenosis is currently a utopian ideal, but a handful of trials and growing clinical experience are showing that better treatment options may be on the horizon.
By Jos C. van den Berg, MD, PhD
Sponsored by Gore & Associates
Case Report: Treating a Long Chronic Total Occlusion in a Patient With CLI
A personalized treatment approach to a challenging case.
By Erik Weekman, BS; Vinayak Subramanian, BS; Ivy Smith, BS; and George L. Adams, MD, MHS, FACC, FSCAI
